Solid Biosciences Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report1 of 5 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
+18.81%
vs ±75.6% implied · ×0.25
shaded = implied · ▲▼ = realized
SentenceIn connection with the asset purchase agreement with FA212 LLC ("FA212"), certain development milestone payments to FA212 are payable in either cash, equity, or a combination of both, at our discretion.
SLDB 10-Kaccession 0001193125-26-115928
SentenceWe have further licensed certain intellectual property from the University of Pennsylvania and others that are important or necessary to the development of SGT-212 and from ICS Maugeri that are important or necessary to the development of SGT-501.
SLDB 10-Kaccession 0001193125-26-115928
SentencePursuant to the Maugeri License Agreement, Maugeri granted us an exclusive worldwide sublicensable license in certain Maugeri patent rights, including existing patent rights, and those in any improvements or know-how made in performance of the Maugeri License Agreement, and a non-exclusive worldwide sublicensable license in certain Maugeri know-how, including existing know-how, and on any improvement thereto, in each case, subject to certain conditions, that is necessary or reasonably useful to develop licensed products under the terms of the Maugeri License Agreement.
SLDB 10-Kaccession 0001193125-26-115928
SentenceIn December 2024, in connection with the execution of our collaboration, patent and know-how license agreement with Mayo Foundation for Medical Education and Research ("Mayo"), we issued 364,990 shares of our common stock to Mayo in a private placement.
SLDB 10-Kaccession 0001193125-26-115928
SentenceWe, and our subsidiary AavantiBio Inc. ("AavantiBio"), have entered into several license agreements with the University of Florida Research Foundation, Inc. ("UFRF").
SLDB 10-Kaccession 0001193125-26-115928
SentenceWe have further licensed certain intellectual property from the University of Pennsylvania and others that are important or necessary to the development of SGT-212 and from ICS Maugeri that are important or necessary to the development of SGT-501.
SLDB 10-Kaccession 0001193125-26-115928
SentenceIn 2015, we entered into a license agreement with the University of Washington, acting through UW CoMotion, under which we obtained an exclusive, royalty-bearing, sublicensable, worldwide license under certain patent applications owned by the University of Washington relating to novel micro-dystrophins to develop, manufacture, and commercialize products for use in the treatment of Duchenne and related disease indications caused by a lack of functional dystrophin.
SLDB 10-Kaccession 0001193125-26-115928
Solid Biosciences has 7 disclosed suppliers and 0 disclosed customers in SEC filings.
Solid Biosciences Inc.
6.20
—
—
Largest filed tie
—
Expected move
No implied move.